RLY-2608的发现与临床概念验证:一种首创的突变选择性变构PI3Kα抑制剂,可将抗肿瘤活性与高胰岛素血症解耦
研究利用分子动力学模拟和冷冻电镜识别PI3Kα的变构网络,并通过DNA编码文库筛选发现首创变构突变选择性抑制剂RLY-2608。RLY-2608在PIK3CA突变异种移植模型中抑制肿瘤生长且对胰岛素影响最小,在两名晚期激素受体阳性乳腺癌患者中产生客观肿瘤缓解,未观察到野生型PI3Kα相关毒性。
要点
- RLY-2608是首创的变构突变选择性PI3Kα抑制剂。
- 在PIK3CA突变异种移植模型中抑制肿瘤生长且对胰岛素影响最小。
- 两名晚期激素受体阳性乳腺癌患者出现客观肿瘤缓解,无野生型PI3Kα相关毒性。
核心结论
- RLY-2608是一种首创的变构突变选择性PI3Kα抑制剂,在患者中展示突变选择性,标志着克服正交PI3Kα抑制剂局限性的临床突变选择性抑制的进展。
研究设计与样本
- 研究采用分子动力学模拟和冷冻电镜识别PI3Kα变构网络,并利用DNA编码文库筛选发现RLY-2608。
- 在PIK3CA突变异种移植模型中评估RLY-2608对肿瘤生长和胰岛素的影响。
- 在两名诊断为晚期激素受体阳性乳腺癌且携带激酶或螺旋域PIK3CA突变的患者中评估RLY-2608的客观肿瘤缓解和毒性。
主要发现
- RLY-2608在PIK3CA突变异种移植模型中抑制肿瘤生长,对胰岛素(葡萄糖稳态失调标志物)影响最小。
- RLY-2608在两名晚期激素受体阳性乳腺癌患者(携带激酶或螺旋域PIK3CA突变)中引发客观肿瘤缓解,未观察到野生型PI3Kα相关毒性。
关键数值与推荐
- PIK3CA(PI3Kα)突变见于约40%的激素受体阳性乳腺癌。
- RLY-2608在两名患者中引发客观肿瘤缓解,未观察到野生型PI3Kα相关毒性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: PIK3CA (PI3Kα) is a lipid kinase commonly mutated in cancer, including ∼40% of hormone receptor-positive breast cancer. The most frequently observed mutants occur in the kinase and helical domains. Orthosteric PI3Kα inhibitors suffer from poor selectivity leading to undesirable side effects, most prominently hyperglycemia due to inhibition of wild-type (WT) PI3Kα. Here, we used molecular dynamics simulations and cryo-electron microscopy to identify an allosteric network that provides an explanation for how mutations favor PI3Kα activation. A DNA-encoded library screen leveraging electron microscopy-optimized constructs, differential enrichment, and an orthosteric-blocking compound led to the identification of RLY-2608, a first-in-class allosteric mutant-selective inhibitor of PI3Kα. RLY-2608 inhibited tumor growth in PIK3CA-mutant xenograft models with minimal impact on insulin, a marker of dysregulated glucose homeostasis. RLY-2608 elicited objective tumor responses in two patients diagnosed with advanced hormone receptor-positive breast cancer with kinase or helical domain PIK3CA mutations, with no observed WT PI3Kα-related toxicities. SIGNIFICANCE: Treatments for PIK3CA-mutant cancers are limited by toxicities associated with the inhibition of WT PI3Kα. Molecular dynamics, cryo-electron microscopy, and DNA-encoded libraries were used to develop RLY-2608, a first-in-class inhibitor that demonstrates mutant selectivity in patients. This marks the advance of clinical mutant-selective inhibition that overcomes limitations of orthosteric PI3Kα inhibitors. See related commentary by Gong and Vanhaesebroeck, p. 204 . See related article by Varkaris et al., p. 227 . This article is featured in Selected Articles from This Issue, p. 201.
引用
- Varkaris A, Pazolli E, Gunaydin H, et al. Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia. Cancer Discov. 2024. PMID: 37916956. doi:10.1158/2159-8290.CD-23-0944
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。